Noom’s Post

In a recent article with The Advocate, Kenny Cole, MD, MHCDS, Vice President of Clinical Improvement and Medical Director of Ochsner Digital Medicine, highlights how Digital Medicine is transforming cardiometabolic condition management.   Ochsner Digital Medicine: ✅ Enables secure monitoring: Uses wireless devices for real-time health data, ensuring precise management of conditions like Type 2 diabetes and high blood pressure ✅ Enhances access and personalization: Offers more accessible and tailored care solutions ✅ Minimizes exposure: Avoids risks from crowded waiting rooms Dr. Cole also says the program can “enable greater levels of access, as well as better meeting a patient’s needs in a more consumer-centric way.” Find out how we can support your population one-on-one clinical support and medication management from anywhere in the country: https://lnkd.in/ea6CQhvX

Check out our most recent blog. “Polycystic Ovarian Syndrome (PCOS): A Comprehensive Management Guide for Healthcare Practitioners” Effective management of PCOS requires a multifaceted approach tailored to the individual’s specific symptoms and underlying causes. By integrating lifestyle modifications, targeted pharmacological treatment, and supportive nutraceuticals, healthcare practitioners can significantly improve the quality of life for women with PCOS. Read the full blog here: https://buff.ly/3zQmgqX

New on-demand web-based activity: Optimizing Ready-to-Administer IV Push Products: A Multidisciplinary Approach to Safety, Cost-Effectiveness, and Patient Outcomes in Health System and Perioperative Settings This educational activity examines the landscape of considerations regarding ready-to-administer IV push products compared with traditional IV vial products, the holistic costs of waste, and new evidence regarding perioperative opioid use and associated adverse clinical outcomes. https://hubs.ly/Q02CVN0j0

Pharmacy burnout and institutional fatigue is at a critical level. #Pharmacist Dr. Angela German discussed often-overlooked contributing factors in a recent Scottsdale Institute webinar. Read our Expert Insight to learn more and access the replay. https://ow.ly/vKUB50QziNL #RetailPharmacy #PharmacistBurnout #FutureReadyPharmacy

Yes, doing nothing can actually cost more❗ Covering medications for the treatment of obesity without a managed program is 2x more costly over a two-year period. A managed program, like the one offered by #WeightWatchers for Business, provides employers with greater clinical efficiency, medication cost savings based on de-escalation and step therapy, and medication use based on appropriate indication. See the white paper for details on how GLP-1s are driving both costs and savings for employers:https://bit.ly/3UB9inh

9 million patients with type 2 diabetes. 1,100 diabetologist practices -> 8,182 patients per specialist. 60,000 general practitioners ->150 patients per GP. Quite obvious that it will be close to impossible to deliver high-quality care to everyone. Especially, since the number of patients is expected to reach 12M by 2024 and then meeting a substantially smaller workforce. We need to fix this. In this video, Perfood founder and Chief Medical Officer Torsten Schröder, MD, PhD explains how we can change the tractory. 1. Truly innovative care solutions, harvesting the power of artificial intelligence. 2. Involving patients: empowering and enabling them to manage their health. Luckily, with hashtag #glucura Perfood developed an innovative solution applying the power of hashtag #cgm and hashtag #artificialintelligence. At the Deutsche Diabetes Gesellschaft (DDG) congress 2024, Dr. Jesuthas Ajendra walked providers through our pilot data in a poster session. Not too spoil anything, but keep an eye open for our soon to be published long-term follow-up data ;)

Norepinephrine dose reporting? No reason to delay standardization! 💉 NE dose has known prognostic implications: dose reporting heterogeneity could bias perception of severity & prognosis, with the risk of triggering early, delayed, inadequate decisions 💉 absolute gap of NE base equivalence wide among different saltbased dose preparation/labeling #FOAMcc 🔓 https://rdcu.be/dISUF Appropriate & consistent dosages reporting critical to avoid untoward consequences to patient safety, clinical practice, prognostication, research activities, guideline development, particularly given widespread use of NE in critically ill. 🔓 https://rdcu.be/dISSr 💉 All refer to editorial on vasopressor dosing focusing on NE 🔓 https://rdcu.be/dGazg

Hear Ipsos experts discuss the evolution of obesity treatments, including clinical efficacy and safety results, HCP and consumer perspectives, market adoption, and the access, reimbursement, and intellectual property (IP) landscapes. https://lnkd.in/ewSAAhn7

The efficacy of GLP-1 medications in managing type 2 #diabetes is well-established in medical literature and clinical practice guidelines. https://bit.ly/3SPWvN1 There's less robust support for the widespread use of pharmacotherapy in the treatment of #obesity as a standard of care, although, as with other chronic diseases, some patients may benefit from medications. We explain how to manage your priorities around Rx #benefits, especially GLP-1s. #healthcare

The efficacy of GLP-1 medications in managing type 2 #diabetes is well-established in medical literature and clinical practice guidelines. https://bit.ly/3TvxEQl There's less robust support for the widespread use of pharmacotherapy in the treatment of #obesity as a standard of care, although, as with other chronic diseases, some patients may benefit from medications. We explain how to manage your priorities around Rx #benefits, especially GLP-1s. #healthcare